An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future. (Q33786150)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21208359%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

review article

1 reference

title

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21208359%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21208359%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21208359%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Signe Sørensen Torekov

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21208359%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21208359%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

U Kielgast

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21208359%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

M Asmar

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21208359%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

5 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21208359%20AND%20SRC:MED&resulttype=core&format=json

Diabetes, Obesity and Metabolism

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21208359%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21208359%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21208359%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

394-407

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21208359%20AND%20SRC:MED&resulttype=core&format=json

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Glucagon-like peptide-1, glucose homeostasis and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Incretin-based therapies: viewpoints on the way to consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-b

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Pharmaceutical strategies utilizing recombinant human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Treatment of type 2 diabetes with incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01357.X

10.1111/J.1463-1326.2011.01357.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21208359%20AND%20SRC:MED&resulttype=core&format=json

release_32e5jdzc2bgcjhqeahmdier34m

19 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/32e5jdzc2bgcjhqeahmdier34m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21208359%20AND%20SRC:MED&resulttype=core&format=json